SAN ANTONIO, July 7, 2014 /PRNewswire/ -- GenSpera, Inc.
(OTCQB: GNSZ), a leader in developing prodrug therapeutics for the
treatment of cancer, announces that interim data from the G-202
Phase I and Phase II trials in hepatocellular carcinoma (HCC)
patients will be presented at the Fifth Annual Asia-Pacific Primary
Liver Cancer Expert (APPLE) Meeting to be held July 11-13th in Taipei, Taiwan.
An oral presentation entitled, "Clinical Activity of G-202, a
Thapsigargin-Based Prostate-Specific Membrane Antigen
(PSMA)-Activated Prodrug, in Patients with Progressive
Hepatocellular Carcinoma (HCC)" will be presented in the poster
discussion session "Treatment for Intermediate – Advanced Stage
Disease" on July 12th from
1:15- 3:00 pm UTC + 8:00.
Devalingam Mahalingam, MD, PhD, principal investigator of the
G-202 Phase II trial in hepatocellular carcinoma (HCC), will
discuss the data obtained to date in patients with HCC treated in
the Phase I and Phase II studies. Dr. Mahalingam is an oncologist
at the Cancer Therapy & Research Center at The University of Texas Health Science Center at
San Antonio, specializing in
identifying novel cancer therapeutics.
The abstract will be published on the company website following
the APPLE Poster Session.
About Asia-Pacific Primary Liver Cancer
Expert
http://www.2014applecongress.org/
About GenSpera
GenSpera's technology platform
combines a powerful, plant-derived cytotoxin (thapsigargin) with a
prodrug delivery system that provides for the targeted release of
drug candidates within a tumor. Unlike typical chemotherapeutic
agents, thapsigargin results in cell death irrespective of the rate
of cell division, which may provide an effective approach to kill
both fast- and slow-growing cancers. GenSpera's lead drug
candidate, G-202, is activated by the enzyme PSMA, which is found
at high levels in the vasculature of liver and glioblastoma cancers
and in the vasculature of almost all other solid tumors. G-202 is
therefore expected to have potential efficacy in a wide variety of
tumor types.
G-202 Phase II clinical trials are underway in both
hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website:
www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking
Information
This news release may contain
forward-looking statements. Investors are cautioned that statements
in this press release regarding potential applications of
GenSpera's technologies constitute forward-looking statements that
involve risks and uncertainties, including, without limitation,
risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or
regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional
information on potential factors that could affect our results and
other risks and uncertainties will be detailed from time to time in
GenSpera's periodic reports filed with the Securities and Exchange
Commission.
CONTACT: |
|
|
|
Company:
|
Craig Dionne, PhD,
CEO
|
|
GenSpera, Inc.
(210)
479-8112
|
|
|
Investors:
|
John
Baldissera
|
|
BPC Financial
Marketing (800) 368-1217
|
|
|
Media:
|
(800) 665
0411
|
SOURCE GenSpera, Inc.